Front Row Advisors LLC Eagle Pharmaceuticals, Inc. Transaction History
Front Row Advisors LLC
- $282 Million
- Q2 2024
A detailed history of Front Row Advisors LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Front Row Advisors LLC holds 40 shares of EGRX stock, worth $36. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 40
-0.0%
Holding current value
$36
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EGRX
# of Institutions
80Shares Held
9.91MCall Options Held
1.01MPut Options Held
0-
Nantahala Capital Management, LLC New Canaan, CT1.96MShares$1.77 Million0.73% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$1.09 Million2.46% of portfolio
-
Citigroup Inc1MShares$901,3990.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT697KShares$627,1170.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA564KShares$507,9560.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $11.7M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...